Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis

BACKGROUND: : The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. METHODS: : We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Türkoğlu, Recai, Baliç, Nesrin, Kızılay, Tuğçe, Erol, Ruziye, Akbayır, Ece, Yılmaz, Vuslat, Tüzün, Erdem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747775/
https://www.ncbi.nlm.nih.gov/pubmed/35033838
http://dx.doi.org/10.1016/j.msard.2022.103524
_version_ 1784630909602889728
author Türkoğlu, Recai
Baliç, Nesrin
Kızılay, Tuğçe
Erol, Ruziye
Akbayır, Ece
Yılmaz, Vuslat
Tüzün, Erdem
author_facet Türkoğlu, Recai
Baliç, Nesrin
Kızılay, Tuğçe
Erol, Ruziye
Akbayır, Ece
Yılmaz, Vuslat
Tüzün, Erdem
author_sort Türkoğlu, Recai
collection PubMed
description BACKGROUND: : The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. METHODS: : We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations. RESULTS: : Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices. CONCLUSION: : Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.
format Online
Article
Text
id pubmed-8747775
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-87477752022-01-11 Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis Türkoğlu, Recai Baliç, Nesrin Kızılay, Tuğçe Erol, Ruziye Akbayır, Ece Yılmaz, Vuslat Tüzün, Erdem Mult Scler Relat Disord Correspondence BACKGROUND: : The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. METHODS: : We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations. RESULTS: : Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices. CONCLUSION: : Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19. Elsevier B.V. 2022-02 2022-01-11 /pmc/articles/PMC8747775/ /pubmed/35033838 http://dx.doi.org/10.1016/j.msard.2022.103524 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Türkoğlu, Recai
Baliç, Nesrin
Kızılay, Tuğçe
Erol, Ruziye
Akbayır, Ece
Yılmaz, Vuslat
Tüzün, Erdem
Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
title Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
title_full Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
title_fullStr Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
title_full_unstemmed Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
title_short Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
title_sort fingolimod impairs inactivated vaccine (coronavac)-induced antibody response to sars-cov-2 spike protein in persons with multiple sclerosis
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747775/
https://www.ncbi.nlm.nih.gov/pubmed/35033838
http://dx.doi.org/10.1016/j.msard.2022.103524
work_keys_str_mv AT turkoglurecai fingolimodimpairsinactivatedvaccinecoronavacinducedantibodyresponsetosarscov2spikeproteininpersonswithmultiplesclerosis
AT balicnesrin fingolimodimpairsinactivatedvaccinecoronavacinducedantibodyresponsetosarscov2spikeproteininpersonswithmultiplesclerosis
AT kızılaytugce fingolimodimpairsinactivatedvaccinecoronavacinducedantibodyresponsetosarscov2spikeproteininpersonswithmultiplesclerosis
AT erolruziye fingolimodimpairsinactivatedvaccinecoronavacinducedantibodyresponsetosarscov2spikeproteininpersonswithmultiplesclerosis
AT akbayırece fingolimodimpairsinactivatedvaccinecoronavacinducedantibodyresponsetosarscov2spikeproteininpersonswithmultiplesclerosis
AT yılmazvuslat fingolimodimpairsinactivatedvaccinecoronavacinducedantibodyresponsetosarscov2spikeproteininpersonswithmultiplesclerosis
AT tuzunerdem fingolimodimpairsinactivatedvaccinecoronavacinducedantibodyresponsetosarscov2spikeproteininpersonswithmultiplesclerosis

Ejemplares similares